Susceptibility testing of clinical isolates of Methylobacterium species
- PMID: 1416844
- PMCID: PMC192022
- DOI: 10.1128/AAC.36.8.1635
Susceptibility testing of clinical isolates of Methylobacterium species
Abstract
Methylobacterium species represent a relatively new genus which is being increasingly isolated from cases of opportunistic infections. This study reports on 3 reference strains and 15 clinical isolates of Methylobacterium species. Susceptibility tests were performed by the agar dilution and commercial broth microdilution methods at both 30 and 35 degrees C. Readings were made at 24, 48, and 72 h. Incubation conditions of 48 h and 30 degrees C were found to be optimum. Both the agar dilution and broth microdilution methods gave equivalent results. Drugs tested and their MICs for 90% of isolates (in micrograms per milliliter) were as follows: amikacin, less than or equal to 1; gentamicin, 1; ciprofloxacin, 1; trimethoprim-sulfamethoxazole, 2/38; ceftriaxone, 16; and ceftizoxime, 16. The majority of our isolates were resistant to six other beta-lactam drugs tested. Nine of the 15 Methylobacterium isolates were beta-lactamase positive.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
